Combined immunotherapy in children with atopic dermatitis: rationale for application

被引：0

作者：

Derkach, V. V. ^{[1
,3
]}

Slavyanskaya, T. A. ^{[2
,3
]}

机构：

[1] Pacific State Med Univ, Vladivostok, Russia

[2] Peoples Friendship Univ Russia, Moscow, Russia

[3] Inst Immunophysiol, Moscow, Russia

来源：

ALLERGY, ASTHMA & IMMUNOPHYSIOLOGY: FROM GENES TO CLINICAL MANAGEMENT | 2014年

关键词：

Atopic dermatitis; children; immunotherapy; allergen-specific immunotherapy; quality of life; ALLERGEN IMMUNOTHERAPY;

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

the study considers advantages of a combination therapy in children with atopic dermatitis (AD) and a rationale for application of multiagent immunotherapy (MIT) including parenteral allergen-specific immunotherapy (PASIT) and an immunomodulator (IM). It has been found that including MIT in the combination therapy of AD for 3 years results in lessening of severity and clinical manifestations of a disease and in improving children's quality of life (QOL).

引用

页码：63 / 67

页数：5

共 8 条

[1] Mechanisms of disease: Atopic dermatitis
Bieber, Thomas
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (14) : 1483 - 1494
[2] Braido F., 2014, ASTHMA COMORBIDITIES, P379
[3] Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review
Compalati, Enrico
Rogkakou, Anthi
Passalacqua, Giovanni
Canonica, Giorgio W.
[J]. CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 12 (04) : 427 - 433
[4] Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis
Kim, Myoung-Eun
Kim, Jeong-Eun
Sung, Joon-Mo
Lee, Jin-Woo
Choi, Gil-Soon
Nahm, Dong-Ho
[J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (09) : 1159 - 1164
[5] SEPIASHVILI R.I., 2012, J ALLERGY IMMUNOLOGY, V13, P284
[6] Allergen-Specific Immunotherapy (ASIT) Effect On Quality of Life (QOL) in Children with Moderate (MAD) and Severe (SAD) Atopic Dermatitis
Slavyanskaya, Tatiana
Derkach, Vladislava
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB100 - AB100
[7] SLAVYASKAYA T. A., 2013, INT J IMMUNOREHABILI, V15, P24
[8] SLAVYASKAYA T. A., 2013, MEDIMOND INT P, P39

← 1 →